woosh,,,,,,,,,,, page-3

8th September 2004
CogState Announces Significant Contractual Agreement with Pfizer
CogState Limited (ASX: CGS) can announce that it has signed a Master Service
Agreement with Pfizer Inc. The Master Service Agreement will provide the contractual
basis for any future use by Pfizer during clinical trials, of CogState’s computerized
cognitive tests.
The Master Service Agreement will reduce time required to document the contractual
terms for any future use of CogState tests by Pfizer.
In addition, CogState has today signed a further agreement with Pfizer, under the Master
Service Agreement, for use of the CogState Diagnostic test in a specific Phase I Clinical
Trial that is being conducted by Pfizer. The Phase I Clinical Trial will provide CogState
with revenue of approximately AUD$60,000 over the coming 2 months.
About CogState: CogState Ltd. was established in 1999 with headquarters in Melbourne, Australia. In
February 2004 the company listed on the Australian Stock Exchange (ASX) as “CGS.” The company
specializes in neuroscience, particularly in the development and commercialization of computer-based tests
for neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease and concussion-related injury.
A division of the company, CogSport, marketed in the U.S. through a partnership with Schutt Sports (the
worlds largest manufacturer of American Football helmets as Concussion Sentinel, is a novel concussion
management tool developed to aid physicians in making confident return-to-play decisions after an athlete
has suffered a concussion. Concussion Sentinel is applicable for use by sporting organizations, medical
professionals, and parents/athletes and provides rapid measurement of cognitive function. Other divisions of
the company focus on providing computer-based measurement tools to pharmaceutical companies for use
during clinical trials. CogState also has a therapeutics division which has in-licensed two drug targets from
leading medical research organisations in Japan and Israel for the treatment of Alzheimer's Disease and
Parkinson's Disease respectively.